Atopic dermatitis (AD) is a chronic, inflammatory skin disease characterized by itchy, painful, and dry skin. Despite the great number of available therapies, economic evaluations are needed to provide evidence on their cost-efficiency to assist the National Health System (NHS) in decision-making. The objective of this study is to evaluate the cost-effectiveness of abrocitinib (200mg) versus dupilumab (300mg), tralokinumab (300mg), baricitinib (2mg/4mg) and upadacitinib (15mg/30mg) in the treatment of adult patients with severe AD who are candidates for systemic treatments from the Spanish NHS perspective.
